Table 6.
Results of downstaging chemotherapy.
| Author | n | Chemotherapeutic agent | N (%) converted to resectable | 5-y survival |
|---|---|---|---|---|
| SYSTEMIC CHEMOTHERAPY | ||||
| Bismuth et al. 1996 (127) | 330 | 5-FU, Leucovorin | 53 (16%) | OS: 40% |
| Adam et al. 2001 (32) | 701 | 5-FU, Leucovorin | 95 (13.5%) | OS: 35–60% large tumors, |
| Adam et al. 2004 (294) | 1104 | 5-FU + oxaliplatin (70%) | 138 (12.5%) | OS: 33% |
| 5-FU + both (4%) | DFS: 22% | |||
| Alberts et al. 2005 (130) | 42 | 5-FU, Leucovorin | 17 (40%) | (Median f/u 22 m) |
| Barone et al. 2007 (295) | 40 | 5-FU, Leucovorin | 19 (47.5%) | OS: 62% |
| REGIONAL CHEMOTHERAPY | ||||
| Clavien et al. 2002 (128) | 23 | HAI Floxuridine | 6 (26%) | -- |
| Kemeny et al. 2009 (129) | 49 | HAI Floxuridine | 23 (47%) | (median f/u 26 m) |
Notes: DFS, disease-free survival; 5-FU, fluorouracil; f/u, follow up; HAI, hepatic arterial infusion. OS, overall survival.